Codexis, Inc.

NASDAQ:CDXS

Biotechnology

Healthcare
$1.15 +0.60%

+$0.02 today

Market cap
$126.04M
Beta
2.48
P/E (TTM)
-7.1
EPS (TTM)
-$0.35
52W Low $0.96High $3.87

Volume 1.47M

Average 1.15M

CDXS Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Codexis, Inc.NASDAQ: CDXS

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 78.3%

Gross margin was 78.3% in Q1 FY2026, up 14.5 pp from a year earlier. On a trailing-twelve-month basis it was 83.9%, up 12.4 pp year over year. Over 3 fiscal years it widened by 14.2 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
78.3%-13.1 pp QoQ
Last fiscal yearDec 2025
86.7%+14.2 pp YoY
LTMMar 2026
83.9%+12.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+14.5 pp——
1 year+14.2 pp——
3 years+14.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
86.7%
Year-over-year change
+14.2pp

Gross Margin vs competitors

How CDXS compares with its peers on the latest reported figures

  • CDXS's LTM Mar 2026 gross margin of 83.9% is the 6th highest of the 9 companies compared; the peer median is 93.4%.
  • Its year-over-year change of +12.4 pp is the highest of 9, against a peer median of -0.6 pp.
  • Over three fiscal years its change of +14.2 pp compares with a peer median of -0.9 pp.
CDXS Competitors Peer median
Gross Margin for CDXS and competitors
Company Period LTM level YoY 3-year change
IPHAInnate Pharma S.A.FY2025100.0% +0.0 pp+89.6 pp
SGMOSangamo Therapeutics, Inc.LTM Mar 2026100.0% +0.0 pp-8.3 pp
RANIRani Therapeutics Holdings, Inc.LTM Mar 202694.9% -5.1 pp—
CCCCC4 Therapeutics, Inc.LTM Mar 202694.8% +9.6 pp-22.2 pp
IVVDInvivyd, Inc.LTM Mar 202692.0% -1.3 pp—
CDXSCodexis, Inc.LTM Mar 202683.9% +12.4 pp+14.2 pp
ARMPArmata Pharmaceuticals, Inc.LTM Mar 202672.2% +1.7 pp+604.5 pp
OABIOmniAb, Inc.LTM Mar 202635.5% -64.5 pp-118.2 pp
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202619.5% -33.1 pp+6.6 pp
TARAProtara Therapeutics, Inc.FY2025— ——
Peer median (excluding CDXS) 93.4%-0.6 pp-0.9 pp

Competitors are the stored peer set for CDXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue104.75M138.59M70.14M59.35M70.39M
Cost of Revenue22.21M38.03M12.81M16.29M9.34M
Gross Profit82.55M100.56M57.33M43.06M61.05M
Gross Margin78.8%72.6%81.7%72.6%86.7%
Research & Development55.92M80.1M58.89M46.26M52.31M
Selling, General & Admin49.32M52.17M53.25M55.15M47.07M
Operating Expenses105.24M135.44M125.4M101.58M99.38M
Depreciation & Amortization5.95M5.4M5.52M4.95M5.25M
EBITDA(15.14M)(26.31M)(49.28M)(53.41M)(33.87M)
EBITDA Margin-14.5%-19.0%-70.3%-90.0%-48.1%
Operating Income(22.7M)(34.88M)(68.07M)(58.52M)(38.33M)
Operating Margin-21.7%-25.2%-97.0%-98.6%-54.5%
Interest Income459K1.44M4.17M3.67M2.63M
Interest Expense00004.81M
Other Income / Expenses1.61M1.57M(8.1M)(6.72M)(5.6M)
Income Before Tax(21.09M)(33.32M)(76.17M)(65.24M)(43.93M)
Pre-Tax Margin-20.1%-24.0%-108.6%-109.9%-62.4%
Income Tax Expense189K276K69K34K47K
Net Income(21.28M)(33.59M)(76.24M)(65.28M)(43.97M)
Net Margin-20.3%-24.2%-108.7%-110.0%-62.5%
EPS (Basic)(0.33)(0.51)(1.12)(0.89)(0.50)
EPS (Diluted)(0.33)(0.51)(1.12)(0.89)(0.50)
Weighted Avg Shares64.57M65.34M68.13M73.41M87.14M
Weighted Avg Shares (Diluted)64.57M65.34M68.13M73.41M87.14M

Codexis, Inc.

NASDAQ:CDXS

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.